Inhibrx Biosciences has 7 investors with a majority stake of 50%. Institutions hold 43% ownership, facing the biggest gain or loss. Hedge funds and individuals also hold significant stakes, with Viking Global Investors LP as the largest shareholder. CEO Mark Lappe owns 6.